Genelabs Technologies Inc.

Heather Criss Keller has been Vice President, Business Strategy since November 2006 and corporate Secretary since 1999, serving as Senior Business Strategy Advisor from 2004 to 2006. From 2001 through 2004 she served as Vice President, General Counsel, before which she was Vice President, Legal Affairs from 2000 to 2001 and Director of Legal Affairs from 1998 to 2000. Ms. Keller served as Senior Corporate Counsel at Heartport, Inc. from 1996 to 1998, prior to which she was an associate with the law firm of Brobeck, Phleger & Harrison LLP. Ms. Keller received a J.D. from Vanderbilt University Law School and a B.A. from Duke University.

Roy J. Wu has been Vice President of Business Development since October 2001. From October 1997 to October 2001, he served as Vice President, Corporate Secretary and member of the board of directors of Kissei Pharma, USA. Prior to joining Kissei, Mr. Wu was Director of Business Development with Quintiles - BRI Inc. for approximately three years and was previously with Syntex for 16 years, in research and development and in business development. He received his B.S. in Biology from University of San Francisco and his M.B.A. in International Finance from University of San Francisco.

Clint Webb is the Director of Legal Affairs and Corporate Secretary at Genelabs Technologies, Inc. As counsel for Genelabs, he has primary responsibility for all corporate, securities, transactional and employment law matters. He also manages intellectual property strategy and prosecution. Mr. Webb is also a regular speaker at the U.C. Davis King Hall School of Law, where he lectures on corporate and securities laws. Prior to Genelabs, Mr. Webb served as Corporate Counsel for Ilypsa, Inc., a privately held biotechnology company focused on therapeutic drugs for renal diseases. He also served as Licensing Counsel for Ilypsa's parent company, Symyx Technologies, Inc., a contract research provider and manufacturer of drug discovery equipment and software. Before joining Symyx, Mr. Webb practiced law privately as an associate attorney with Morrison & Foerster, LLP, where he counseled public and privately held clients through entity formation, venture capital financings, merger & acquisition transactions, licensing and collaborative research arrangements, employee stock option matters and initial public offerings. In 1998, Mr. Webb received a J.D. degree from the U.C. Davis King Hall School of Law, where he was a Member of the U.C. Davis Law Review and a Sr. Articles Editor of the Journal of International Law and Policy. In 1991, Mr. Webb received a B.A. degree in English Literature from U.C. Berkeley.

Dr. Cantor is Chief Scientific Officer and Chairman of the Scientific Advisory Board for Sequenom joining them in 1998. In May 2000, Dr. Cantor was appointed to the Company's board of directors. He was previously the chair and professor of the department of biomedical engineering and biophysics, and Director of the Center for Advanced Biotechnology at Boston University. Prior to that time, Dr. Cantor held positions at Columbia University and the University of California, Berkeley. He was also Director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory. A world-renowned scientist, Dr. Cantor is a consultant to more than 16 biotech firms, has published more than 400 peer reviewed articles, been granted 54 US patents, and co-authored a three-volume textbook on Biophysical Chemistry. He published the first textbook on genomics entitled, Genomics: The Science and Technology of the Human Genome Project.

Matthew J. Pfeffer has been our Corporate Vice President and Chief Financial Officer since April 2008. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer serves on boards and advisory committees of the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer has a bachelor’s degree in Accounting from the University of California, Berkeley and is a Certified Public Accountant.